Dom Vigil

Dom Vigil is the Senior Director of Exploitation and Disruption at Photys. Dom has over fifteen years of experience in the pharmaceutical and biotech industries. Dom Vigil received their BS in Biology from the University of New Mexico in 2003 and their PhD in Biological Sciences from Vanderbilt University in 2010. Dom did their postdoctoral training at the University of North Carolina at Chapel Hill from 2010-2013.

Dom Vigil began their industry career as a Research Fellow at Vanderbilt University from 2013-2014. Dom then transitioned to a Staff Scientist position at Genzyme, where they worked on developing small molecule therapeutics for rare genetic diseases. In 2015, they joined Agios Pharmaceuticals as a Scientist and was quickly promoted to Senior Scientist. While at Agios, Dom made significant contributions to the advancement of multiple programs in oncology and cellular metabolism.

In 2017, Dom Vigil joined Kymera Therapeutics as an Associate Principal Scientist and was promoted to Principal Scientist in 2019. At Kymera, they led a team of scientists focused on the discovery and development of first-in-class small molecule therapeutics targeting the ubiquitin system.

In 2020, Dom Vigil left Kymera to join Photys as the Senior Director of Exploitation and Disruption. In this role, they are responsible for leading the company’s efforts to identify and develop novel therapeutic targets and technologies.

Dom Vigil has a Ph.D. in Bichemistry from the University of California, San Diego and a B.S. in Chemistry from the New Mexico Institute of Mining and Technology.

Dom Vigil reports to Ed Holson, CSO. Michael Begley - AD Biology, Alex Lantermann - Dir. Trans. Bio report to Dom Vigil. Some of their coworkers include Alex Hird - VP Chemistry Programs, AJ Campbell - Sr. Dir. CADD, and Flo Wagner - VP Chemistry Platform.